Second-Generation Long-Acting Injectable Antipsychotics: A Comprehensive Assessment of Effectiveness, Safety, and Cost
Petru Ifteni, Paula-Simina Petric, Andreea Violeta Popa, Andreea Teodorescu, Radu Georgescu, Mihnea Costin Manea · 2026
Read Second-Generation Long-Acting Injectable Antipsychotics: A Comprehensive Assessment of Effectiveness, Safety, and Cost by Petru Ifteni, Paula-Simina Petric, Andreea Violeta Popa, Andreea Teodorescu, Radu Georgescu, Mihnea Costin Manea (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13295001.txt.
Description
Petru Ifteni and colleagues survey Romanian psychiatrists about long-acting injectable antipsychotics in a 2026 study. Injections given every few weeks can improve adherence and cut relapse in schizophrenia, yet they remain underused. Views were gathered from doctors treating more than 1,000 patients in total.
Eighty psychiatrists rated the four products sold in Romania on benefit, safety, dosing, and monitoring needs. Aripiprazole injections scored best overall, while olanzapine scored lowest on most counts. Better adherence and fewer relapses most encouraged prescribing, named by almost all respondents. Patient distrust and patchy hospital supply were the leading barriers, pointing to fixes beyond the clinic room.
Catalog record
| CREATOR | Petru Ifteni, Paula-Simina Petric, Andreea Violeta Popa, Andreea Teodorescu, Radu Georgescu, Mihnea Costin Manea |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45817 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |